Steroid receptors in prostate cancer tissues and cells: pathophysiology, problems in methodology, clinical value and controversial questions.
This paper reviews basic and clinical aspects of human prostate cancer, with special regard to steroid hormones and growth factors, their receptors and the use of these tools in clinical practice. Unlike other endocrine-related tumours, such as breast and endometrial cancer, human prostatic carcinoma has distinctive features that crucially hinder its definition in terms of both biological potential and clinical course. Failure of androgen receptors to represent helpful discriminants for both prognosis and treatment of prostate cancer patients may depend upon methodological pitfalls and/or the heterogeneous composition of most tumour tissues. The former involve either technical problems (tissue sampling and storage, assay procedures) or biochemical and biological points (heterogeneity and functional integrity of steroid binding sites, subcellular and tissue distribution of steroid receptors). The latter mostly concern the unique feature of both normal and diseased prostate gland to present regional diversities in hormone sensitivity and steroid receptor content. Another important area of interest resides in the potential role played by stromal-epithelial interaction in the regulation of growth and function of prostate epithelial cells. In this respect, continued growth of androgen-dependent prostate cancer cells is achieved through intricate pathways where mesenchymal steroid-induced polypeptide growth factors may act in a paracrine/autocrine fashion to mediate androgen action on tumor epithelial cells. In particular, epidermal growth factor (EGF) and transforming growth factor-a (TGFa) may serve as androgen intermediaries in the proliferative control of prostate epithelial cells, but may also be involved in androgen-independent autocrine epithelial cell growth. Clinical correlations of androgen receptors in human prostatic carcinoma have been insofal disappointing. Biochemical or histochemical assays have failed to satisfactorily predict prognosis and response to endocrine therapies of patients. This recalls problems in both methodologies and tissue suitability and points to the need of prolonged follow-up studies wherein special care is placed in sampling conditions, identification of high-affinity sites of steroid binding and selection of threshold values for receptor concentrations. Assay of the EGF receptors might provide additional contribution for a deeper inspection of the biological nature of prostate tumour tissues and help in selecting more appropriate individual-based therapeutic strategies.
Pavone-Macaluso
M
M
Institute of Urology, University Medical School, Palermo, Italy.
Carruba
G
G
Castagnetta
L
L
D000728:Androgens / Q000502:physiology; D001665:Binding Sites; D004815:Epidermal Growth Factor / Q000502:physiology; D004848:Epithelium / Q000502:physiology; D066246:ErbB Receptors / Q000502:physiology; D006801:Humans; D008297:Male; D011467:Prostate / Q000254:growth & development; D011471:Prostatic Neoplasms / Q000737:chemistry / Q000473:pathology / Q000503:physiopathology; D011944:Receptors, Androgen / Q000032:analysis; D011987:Receptors, Steroid / Q000032:analysis / Q000502:physiology; D017154:Stromal Cells / Q000502:physiology
D000728:Androgens; D011944:Receptors, Androgen; D011987:Receptors, Steroid; D004815:Epidermal Growth Factor; D066246:ErbB Receptors